Could soluble urokinase plasminogen receptor (suPAR) be used as a diagnostic biomarker for ventilator-associated pneumonia?

Autor: Sunnetcioglu A; Department of Chest Diseases, Yuzuncu Yil University Medical Faculty, Van, Turkey., Sunnetcioglu M; Department of Infectious Diseases, Yuzuncu Yil University Medical Faculty, Van, Turkey., Adıyaman F; Department of Infectious Diseases, Yuzuncu Yil University Medical Faculty, Van, Turkey., Binici I; Department of Infectious Disease, Ercis State Hospital, Van, Turkey., Soyoral L; Department of Anesthesiology and Intensive Care, Yuzuncu Yil University, Medical Faculty, Van, Turkey.
Jazyk: angličtina
Zdroj: The clinical respiratory journal [Clin Respir J] 2017 Nov; Vol. 11 (6), pp. 925-930. Date of Electronic Publication: 2016 Feb 09.
DOI: 10.1111/crj.12438
Abstrakt: Background: Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker that is increasingly used for evaluation of systemic inflammation. This study was performed to investigate whether suPAR may possess a diagnostic value in patients with ventilator-associated pneumonia (VAP).
Methods: This clinical study was performed in the anesthesia intensive care units (ICUs) of our university. In addition to descriptive data, WBC, serum levels of C-reactive protein (CRP) and suPAR prior to and after development of VAP were noted and compared in 31 patients (22 men, 9 women) diagnosed with VAP (Study Group) and 19 patients without VAP (Control Group) in ICU (14 men, 5 women).
Results: The suPAR (P = 0.023), CRP (P = 0.037), WBCs (P = 0.024) in patients with VAP were significantly higher than patients without VAP. There was no remarkable difference in terms of WBCs (P = 0.052) and suPAR levels (P = 0.616) between groups on the first day of connection to mechanical ventilator. The suPAR and CRP levels in patients with VAP were significantly higher than prior to development of VAP (P = 0.001 for both). Area under curve value after diagnosis of pneumonia was found 0.248 (P = 0.002).
Conclusion: To conclude, our results suggest that suPAR can be a useful diagnostic biomarker in patients with VAP. However, clinical trials on larger series are warranted to explore the clinical significance more accurately.
(© 2016 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje